Adherium (ASX:ADR)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Adherium.
RELATED STOCKHEAD STORIES
Health Check: Which biotech boards are at risk of a ‘second strike’?
Air supply: The ASX medtechs tackling respiratory illnesses
The ASX biotechs with secured FDA clearances in 2024, and others looking likely
Rise and Shine: Everything you need to know before the ASX opens
Closing Bell: Tech, Retail, and Banking stocks feel the heat as ASX tumbles over 1pc
ASX Small Caps Lunch Wrap: Whose bark could be worse than their flight this week?
Top 10 at 10: This is what happens when AstraZeneca selects your tech for a clinical trial
Adherium’s focus on US market could pay off big time for its novel asthma device
Closing Bell: Geopolitical tensions, China’s economy roil the ASX as Aussie dollar trades below US65c
Top 10 at 10: Piedmont gets green light to build ‘one of the lowest cost, most sustainable lithium hydroxide operations in the world’
Check Up: Earnings season is almost here. Here’s how ASX biotech investors should read the 4C Report
Check Up: The reason people quit weight-loss drugs
Top 10 at 11: Major gains for sustainable ag after Roots flies a shipment out of Israel
